Avacta Group plc ( (GB:AVCT) ) just unveiled an update.
Avacta Group plc has applied for a block listing of 6,500,000 ordinary shares on AIM to facilitate the trading of shares following the exercise of options under its LTIP/ESOS Scheme. This move is expected to become effective on May 14, 2025, and will allow new ordinary shares to be issued and admitted to trading, maintaining parity with existing shares. The announcement highlights Avacta’s commitment to expanding its market presence and providing transparency to shareholders regarding share capital changes.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company focused on developing innovative, targeted oncology drugs. The company utilizes its proprietary pre|CISION® platform, a tumor-specific protease delivery system, to enhance the efficacy of cancer therapies while minimizing damage to normal tissues. Avacta’s pipeline includes pre|CISION® peptide drug conjugates and Affimer® drug conjugates, offering advantages over traditional antibody drug conjugates.
Average Trading Volume: 1,924,918
Technical Sentiment Signal: Sell
Current Market Cap: £130.4M
See more insights into AVCT stock on TipRanks’ Stock Analysis page.